Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Dec;12(1):1717-1720.
doi: 10.1080/21505594.2021.1939924.

COVID-19 variants as moving targets and how to stop them by glycoengineered whole-virus vaccines

Uri Galili  1
Affiliations
Comment

COVID-19 variants as moving targets and how to stop them by glycoengineered whole-virus vaccines

Uri Galili. Virulence. 2021 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declares a potential indirect competing interest: The author is the inventor in US patents 9662383 and 10201601 (Assignee, University of Massachusetts), which include a method for formation of influenza virus vaccine and which is mentioned indirectly in ref. 8 in this manuscript.

Figures

Figure 1.
Figure 1.
Hypothesis on harnessing of the natural anti-Gal antibody for increased efficacy of inactivated SARS-CoV-2α-gal whole-virus vaccine. Vaccinating SARS-CoV-2α-gal binds the natural anti-Gal antibody at the vaccination site and activates the complement system to generate complement cleavage chemotactic peptides that recruit APC such as dendritic cells and macrophages. Anti-Gal/SARS-CoV-2α-gal immune-complexes are targeted for active, extensive uptake by APC, following binding of the Fc portion of immunocomplexed anti-Gal to Fcγ receptors (FcγR) on APC. Such uptake may be mediated also by C3b/CR1 interaction. The APC transport internalized SARS-CoV-2α-gal to regional lymph nodes, process and present the immunogenic viral peptides on class-I and class-II MHC molecules for activation of virus-specific CD8+ and CD4+ T cells, respectively. TCR-T-cell receptors. Modified with permission from Galili U. “The natural anti-Gal antibody as foe turned friend in medicine” Academic Press/Elsevier, London, 2018, page 153
See this image and copyright information in PMC

Comment on

References

    1. van Oosterhout C, Hall N, Ly H, et al. COVID-19 evolution during the pandemic - implications of new SARS-CoV-2 variants on disease control and public health policies. Virulence. 2021;12:507–508. - PMC - PubMed
    1. Lauring AS, Hodcroft EB.. Genetic variants of SARS-CoV-2-what do they mean? JAMA. 2021;325:529–531. - PubMed
    1. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature. 2003;422:307–312. - PubMed
    1. Watanabe Y, Bowden TA, Wilson IA, et al. Exploitation of glycosylation in enveloped virus pathobiology. Biochim Biophys Acta. 2019;1863:1480–1497. - PMC - PubMed
    1. Watanabe Y, Allen JD, Wrapp D, et al. Site-specific glycan analysis of the SARS-CoV-2 spike. Science. 2020;369:330–333. - PMC - PubMed